President Donald Trump announced on Thursday a drug pricing deal with Regeneron to lower the cost of its pharmaceutical products as part of the White House's signature drug pricing initiative. According to multiple reports, the agreement involves price reductions for all current and future Regeneron drugs on Medicaid, as well as selling a cholesterol drug called Praluent for $225 on the TrumpRx website.
Key Takeaways
President Donald Trump announced a drug pricing deal with Regeneron to lower costs for Medicaid patients and offer a cholesterol drug at $225 on the TrumpRx website. The agreement is part of the administration's efforts to reduce U.S. drug prices to levels seen in other developed nations.
- President Trump announces drug pricing deal with Regeneron
- Deal includes price reductions for Medicaid drugs and discounted Praluent on TrumpRx
- Regeneron commits $27 billion to U.S. research, development, and manufacturing
- FDA approves Otarmeni, a gene therapy for rare hearing loss, available free in the U.S.
- Democrats scrutinize FDA voucher program used for expedited approval
The deal is one of many so-called most-favored-nation deals the Trump administration has made with drug companies to bring U.S. pharmaceutical prices in line with those in other developed nations. Regeneron is the final company among 17 major pharmaceutical firms that received letters from the White House last July regarding this issue.
As part of the new deal, Regeneron has also committed to spending $27 billion on research, development, and manufacturing in the U.S., according to a White House fact sheet. Additionally, Regeneron announced that Otarmeni, its new gene therapy for a rare form of congenital hearing loss, had been approved by the Food and Drug Administration (FDA) and would be made available at no charge to clinically eligible individuals in the U.S.
The FDA approval was expedited under the agency's Commissioner's National Priority Voucher program. This program has faced scrutiny from Democrats in Congress for months, as it has not been authorized by Congress. House and Senate lawmakers have noted that FDA vouchers have repeatedly gone to companies agreeing to pricing concessions sought by the White House.
Even as Trump and his Department of Health and Human Services have touted these drug-pricing deals as transformative, the details of the agreements have not been made public. Pressed by members of Congress to share the contracts this week, Health Secretary Robert F. Kennedy Jr. said his team would share whatever details it could that didn't include proprietary information or trade secrets.
How this summary was created
This summary synthesizes reporting from 4 independent publishers using AI. All sources are cited and linked below. NewsBalance is a news aggregator and media literacy tool, not a news publisher. AI-generated content may contain errors or inaccuracies — always verify important information with the original sources.